scholarly journals Comparison of detection rate of high risk HPV infection between self-collected HPV testing and clinician-collected HPV testing in cervical cancer screening

2019 ◽  
Vol 58 (4) ◽  
pp. 477-481 ◽  
Author(s):  
Pattiya Nutthachote ◽  
Shina Oranratanaphan ◽  
Wichai Termrungruanglert ◽  
Surang Triratanachat ◽  
Arkom Chaiwongkot ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Detection Rate ◽  
Hpv Infection ◽  
Hpv Testing ◽  
High Risk Hpv

scholarly journals Review of Research on the Prevention of HPV Infection and Cervical Cancer

2016 ◽  
Vol 5 (2) ◽  
pp. 39-43
Author(s):  
Tao Wang
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Epidemiological Survey ◽  
Hpv Infection ◽  
Hpv Testing ◽  
Prevention And Treatment ◽  
Preventive Vaccination ◽  
High Risk Hpv

AbstractWorldwide, cervical cancer remains as one of the most common malignancies that threaten women's health. An epidemiological survey has shown that high-risk chronic HPV infection is the leading cause of cervical cancer. Thus, the prevention of HPV infection is the main approach to the prevention and treatment of cervical cancer. Sexual behavior, individual immunity, and age are important cofactors in the promotion of HPV infection. Preventive measures that have been gradually implemented worldwide have significantly decreased the incidence of cervical cancer in recent years. These measures include preventive vaccination against common high-risk HPV and cervical cancer screening, which includes HPV testing. HPV testing in cervical cancer screening has received increased attention and provides the basis for the prevention and treatment of cervical cancer. Given that HPV infection rates significantly vary from region to region, procedures for cervical cancer screening should be improved based on regional differences.

scholarly journals Prevalence of High-risk Human Papillomavirus Infection Among Prisoners in the Nsawam Medium Security Prison, Ghana

2020 ◽  
Author(s):  
Lawrence Kofi Acheampong ◽  
Kofi Effah ◽  
Joseph Emmanuel Amuah ◽  
Ethel Tekpor ◽  
Comfort Mawusi Wormenor ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Prevalence Rate ◽  
Prison Population ◽  
Hpv Infection ◽  
Thermal Coagulation ◽  
Hpv Test ◽  
High Risk Hpv

Abstract Background: The Ghana Prisons Service has a Health Directorate that ensures delivery of healthcare to people in their custody under the Ghana Association of Quasi Health Institution (GAQHI) which is one of the agencies under the Ministry of Health. Across Ghana, females comprise 1.2% of the entire prison population (n=15,463). Cervical cancer screening services are however nonexistent and the prevalence of cervical precancer is undocumented. Our aim was to determine the prevalence of high-risk HPV infection and associated cervical abnormalities during a cervical cancer screening outreach. Methods: After informed consent and counselling, women underwent a structured questionnaire-based interview. Responses were recorded directly into a Microsoft Excel spreadsheet. Inmates were co-tested for cervical pre-cancer by two trained nurses using dry brush cervical samples for 15 high risk HPV types using the AmpFire HPV test after which mobile colposcopy with the EVA system was performed. EVA images were reviewed by a gynecologist. Frequencies and percentages were used to describe categorical data while means and standard deviations or medians and interquartile ranges were used to describe continuous data. Results: The majority (75%) of the inmates were convicts with a median sentence of 5 years. Their mean age was 41.1 years (range, 19–97). Out of the 14% that had ever been screened for cervical cancer, 75% had only been screened once. The self-reported prevalence rate of HIV among the inmates was 13.1%, all of who were receiving treatment. The high-risk HPV prevalence rate was 47.6% in the general population of inmates and 63.6% among HIV positive inmates. Using the EVA system, 5(6%) had lesions on the cervix of which 3(3.6%) were treated with thermal coagulation and 2(2.4%) were treated with LEEP. The average age of high-risk HPV positive inmates was 37.8 years. These inmates were also more likely to have been in prison for a shorter duration. Conclusion: There is a high prevalence of high-risk HPV infection among women in custody. These women will benefit from structured cervical cancer prevention services, including treatment for abnormalities that are picked up during such screening.

scholarly journals Human papillomavirus infections and cervical cancer screening in Tunisian women

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
H Bouguerra ◽  
A Hechaichi ◽  
H Letaief ◽  
M Ardhaoui ◽  
E Ennaiefer ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Cervical Screening ◽  
Public Health Problem ◽  
Hpv Infection ◽  
High Risk Hpv ◽  
National Prevalence

Abstract Background Human papillomavirus (HPV) infections are a significant public health problem with global estimations over 520 000 new cases and 274 000 deaths due to cervical cancer. In Tunisia, cervical cancer is the third cause of cancer in women but only a few prevalence studies conducted in specific populations are available. The present study aims to estimate the national prevalence of HPV infection and cervical cancer testing among Tunisian women. Methods We conducted a population-based cross-sectional study in 2014. We included all sexually active women aged 18 years and older, present in primary health care centers the day of the study. Data collection was based on a standardized questionnaire including socio-demographic data, high-risk behaviors and previous cervical screening. HPV detection and typing was only done for betaglobin positive PCR-test. Ethical considerations were respected. Results The total number of surveyed women was 1494 and the overall prevalence of HPV infection was 7.5% IC95% [5.9%-9.0%]. The most common genotypes were HPV6 (21.9%) and HPV16 (11.5%). Prevalence of high-risk HPV was higher than low-risk HPV; 4.8% IC95% [3.7%-6.2%] and 3.8% IC95% [2.8%-4.8%] respectively. The prevalence of previous cervical screening was 36.6% (95% CI [34.3%-39.2%]). This rate was significantly associated with age (p < 10-3); from 13.9% among those <30 years to 49.3% among those ≥ 50 years. Conclusions Our survey provides an important overview of the current situation of HPV infection among Tunisian women. National prevalence of HPV infection was 7.5% but only 36.6% of women had a previous cervical cancer screening. This coverage remains poor, thus the need of targeted education and encouraging strategies to reduce cervical cancer burden in Tunisia. Key messages National prevalence of HPV infection is not negligeable in Tunisia, especially high risk HPV infections. Cervical screening is still low among Tunisian women, hence the need for education targeted to this population.

scholarly journals Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women

2014 ◽  
Vol 21 (1) ◽  
pp. 30-37 ◽  
Author(s):  
Annarosa Del Mistro ◽  
Helena Frayle ◽  
Antonio Ferro ◽  
Susanna Callegaro ◽  
Annamaria Del Sole ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Routine Practice ◽  
Hpv Testing ◽  
One Year ◽  
High Risk Hpv

Role of Ancillary Techniques in Gynecologic Cytopathology Specimens

2019 ◽  
Vol 64 (1-2) ◽  
pp. 63-70
Author(s):  
Andrea D. Olivas ◽  
Julieta E. Barroeta ◽  
Ricardo R. Lastra
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Hpv Testing ◽  
Invasive Procedures ◽  
Ki 67 ◽  
Dual Staining

The association between high-risk genotypes of human papillomavirus (hr-HPV) and cervical cancer is well established. As hr-HPV testing is rapidly becoming a part of routine cervical cancer screening, either in conjunction with cytology or as primary testing, the management of hr-HPV-positive women has to be tailored in a way that increases the detection of cervical abnormalities while decreasing unnecessary colposcopic biopsies or other invasive procedures. In this review, we discuss the overall utility and strategies of hr-HPV testing, as well as the advantages and limitations of potential triage strategies for hr-HPV-positive women, including HPV genotyping, p16/Ki-67 dual staining, and methylation assays.

scholarly journals Evaluation of the SureX HPV Genotyping Test for the Detection of High-Risk HPV in Cervical Cancer Screening

2020 ◽  
Author(s):  
Baojun Wei ◽  
Ping Mei ◽  
Shengkai Huang ◽  
Xueting Yu ◽  
Tong Zhi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
Cervical Intraepithelial Neoplasia Grade ◽  
Agreement Rate ◽  
Hpv Genotyping ◽  
Hpv Test ◽  
Hpv Types ◽  
High Risk Hpv

Abstract Background: The SureX HPV genotyping test (SureX HPV test), which targets the human papillomavirus (HPV) E6/E7 genes was compared with the Cobas 4800 and Venus HPV tests for detecting 14 high-risk HPV (HR-HPV) types in clinical referral and follow-up patients to evaluate its value for cervical cancer screening.Methods: Two different populations were enrolled in the study. The first population comprised 185 cases and was used for comparing the SureX HPV test (Health, China) with the Cobas 4800 test (Roche, USA). The second population comprised 290 cases and was used for comparing the SureX HPV test (Health, China) with the Venus HPV test (Zhijiang, China). Polymerase chain reaction (PCR) sequencing was performed for further confirmation of discordant results.Results: In the first population, the overall agreement rate was 95.3% for 14 High-Risk HPV types. Eight discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 75.0% between the SureX HPV test and PCR sequencing and 25.0% between the Cobas 4800 test and PCR sequencing (P<0.01). In the second population, the overall agreement rate was 94.5%. Thirteen discordant cases were confirmed by PCR sequencing, which showed that the agreement rates were 76.9% between the SureX HPV test and PCR sequencing and 23.1% between the Venus HPV test and PCR sequencing (P<0.01). With cervical intraepithelial neoplasia grade 2+ (CIN2+) as the reference standard, the sensitivity values of the SureX HPV test and the Venus HPV test were 93.5% and 92.0%, (P>0.05), while the specificity values were 43.3% and 46.7%, respectively (P>0.05).Conclusion: The SureX HPV test had good consistency with both the Cobas 4800 and Venus HPV tests for 14 HR-HPV types. In addition, it avoided some false negatives and false positives. Therefore, the SureX HPV test can be used for cervical cancer screening.

Sign in / Sign up

Export Citation Format

Share Document